[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.61.50. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 23, 1948

HAZARDS OF THIOCYANATE THERAPY IN HYPERTENSION

Author Affiliations

Chicago

From the Departments of Medicine, Northwestern University and St. Joseph Hospital.

JAMA. 1948;138(8):549-551. doi:10.1001/jama.1948.02900080007002
Abstract

The evaluation of any therapeutic agent in the treatment of essential hypertension is exceedingly difficult, because there is a tendency for exacerbations and remissions to occur spontaneously. Much has been written about the cures, but little about failure. In recent years thiocyanates have been used enthusiastically. This is an example of a custom, not too rare, of reviving and injecting new enthusiasm into ancient discarded treatments. The story of the thiocyanates began in 1903 with Pauli, who suggested the use of potassium thiocyanate as a hypotensive agent. The drug was little used until Westphal in 1924 presented a favorable report. In a few years the thiocyanates again fell into disrepute because of the frequency of toxic manifestations, until Barker in 1936 controlled the toxic effects by checking the level of thiocyanates in the blood. Since then numerous observers have concluded that the continuous administration of the drug under adequate control

First Page Preview View Large
First page PDF preview
First page PDF preview
×